StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) company profile

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

About Mineralys Therapeutics

Pharmaceutical Preparations, SIC 2834

This biopharmaceutical company specializes in developing targeted therapies for cardiorenal metabolic conditions linked to dysregulated aldosterone. Its lead product candidate, lorundrostat, is an oral, selective aldosterone synthase inhibitor aimed at controlling conditions such as uncontrolled or resistant hypertension, chronic kidney disease, and obstructive sleep apnea. Because the candidate remains under clinical investigation and regulatory review, the enterprise currently has no approved commercial offerings, established sales segments, or direct product customers.

Operationally, the business does not operate internal manufacturing facilities and relies entirely on external contract organizations to produce raw materials and clinical supply. The provided text notes that development rights originate from a worldwide license with an Asian pharmaceutical partner and outlines clinical trials conducted across adult patient cohorts, but it specifies no facility counts, office locations, or headquarters.

Summary of the business section of Mineralys Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Mineralys Therapeutics, Inc.
Founded
2019
Headquarters
Radnor, PA
Address
150 N. Radnor Chester Road, Suite F200
Phone
(888) 378-6240
Employees
76, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Denver, Colorado

Stock & identifiers

Ticker
MLYS
Exchange
Nasdaq
IPO date
Feb 10, 2023
Shares outstanding
88M, Aug 3, 2026
Public float
$676.00M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1933414
CUSIP
603170101
ISIN
US6031701013
FIGI
BBG00ZXN1GN3
Share class FIGI
BBG00ZXN1GR9
EIN
84-1966887

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jon CongletonChief Executive Officer, Director528,621
Eric WarrenChief Commercial Officer45,838
David Malcom RodmanChief Medical Officer51,384
James J. Ferguson IIIChief Medical Officer102,400
Adam Scott LevyCFO and Secretary48,538
Lonnel CoatsDirector12,400
Kristine PetersonDirector12,400
Brian Taylor SlingsbyDirector7,811,918
Daphne KarydasDirector6,200
Capital Healthcare Fund LP RADirector1,873,429
Rajeev M. ShahDirector5,825,521
RA Capital Nexus Fund III, L.P.Director4,280,051
Peter KolchinskyDirector–
Ra Capital Management, L.P.Director5,456,521
Glenn SblendorioDirector6,200
Derek DiRoccoDirector6,200
Alexander M. GoldDirector6,200
Srinivas AkkarajuDirector5,877,218

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payTotalvs. prior year
Jon Congleton
President and Chief Executive Officer
$636.50K–$4.44M$472.60K$5.54M+2%
Adam Levy
Chief Financial Officer and Secretary
$532.00K$25.00K$1.32M$323.19K$2.20M-23%
David Rodman, M.D.
Chief Medical Officer
$533.00K$25.00K$1.32M$323.80K$2.20M-23%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 10, 2023
Offer price
$16.00
Securities offered
12,000,000
Gross proceeds
$192.00M
Exchange
Nasdaq
First trading day
Feb 10, 2023
First-day close
$18.44+15.3%
Lock-up ends (est.)
Aug 9, 2023

“_________________ Per Share Total Public offering price $ 16.00 $ 192,000,000 Underwriting discount (1) $ 1.12 $ 13,440,000 Proceeds, before expenses, to us $ 14.88 $ 178,560,000 (1) We refer you to “Underwriting” for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 76 full-time employees, of whom 39 were primarily engaged in research and development.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?